UK Cancer Drugs Fund Debuts To Muted Applause From Pharma, Charities
The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.
You may also be interested in...
NICE has given the go-ahead for routine NHS commissioning of seven cancer drugs/indications that were listed on the Cancer Drugs Fund before it was overhauled earlier this year. A total of 35 product indications are up for reappraisal under the program.
On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.
Bayer AG's CEO for the UK and Ireland, Dr. Alexander Moscho, outlines his concerns about the reformed cancer drugs reimbursement system in England and Wales, which in October 2016 saw the first new drug introduced since an overhaul and relaunch earlier this year. Moscho also highlights his worries around proposals from NICE to introduce fees for appraisals of new medicines for use on the National Health Service, which he believes could taint the health technology appraisal committee's reputation and generate skepticism around its independence from industry.